Ghrelin, Growth Hormone and Growth Factors at High Altitude

Healthy Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00966134
• Other study ID #: EK 411
• Status: Completed
• Phase: N/A
• First received: August 24, 2009
• Last updated: February 22, 2010
• Start date: April 2002
• Est. completion date: September 2005

Study information

• Verified date: August 2009
• Source: Medical University of Vienna
• Contact: n/a
• Is FDA regulated: No
• Health authority: Austria: EthikkommissionAustria: Federal Ministry for Health Family and Youth
• Study type: Observational

Clinical Trial Summary

Regulation of ghrelin, growth hormone and growth factors at high altitude and their change during ascent to high altitude has not been studied in depth yet. The study includes 33 volunteers (12f) investigated at sea level, 4 days after ascent to 3440m and 14 days after ascent to 5400-5900m.

The investigators hypothesized that during ascent growth hormone levels would increase to compensate for the higher energy needs at high altitude.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 0
• Est. completion date: September 2005
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Healthy and good physical fitness

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• Growth Hormone
• Healthy

Intervention

Other:
• exposure to high altitude

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Medical University of Vienna

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Ghrelin, growth hormone, insulin-like growth factor I (IGF-I), IGF binding protein 1 (IGFBP1), IGF binding protein 2 (IGFBP2), IGF binding protein 3 (IGFBP3), acid-labile subunit (ALS), insulin, prolactin		14 days	No